PyInvesting

Market research

ABL.F Abbott Laboratories

F EUR Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
155B
P/E ratio
33.37
Analyst target
132.05
Dividend yield
2.8%
Beta
0.59

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Abbott Laboratories is currently in a long term uptrend where the price is trading 4.6% above its 200 day moving average.

From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.2.

Abbott Laboratories's total revenue rose by 28.7% to $11B since the same quarter in the previous year.

Its net income has increased by 106.1% to $2B since the same quarter in the previous year.

Finally, its free cash flow grew by 57.4% to $3B since the same quarter in the previous year.

Based on the above factors, Abbott Laboratories gets an overall score of 5/5.